BOGOTÁ, Colombia (April 22, 2016) – Jon Ruiz, President and CEO of PharmaCielo Ltd., a privately held global company with operations in Colombia focused on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products throughout the world, made the following statement today:
“On behalf of PharmaCielo Ltd. I want to thank the Government of Colombia and President Santos for taking the necessary steps to encourage their colleagues at the United Nations to recognize the real harms caused by the illicit international drug trade and seek out a progressive new strategy to address the world drug problem.
“Regardless of the outcome of the United Nations General Assembly Special Session on the World Drug Problem (UNGASS 2016) meetings and resolutions, the reality is that without Colombian leadership these meetings and discussions would not have been entered into, and they represent an important first step in addressing an ongoing problem.
“No country knows better than Colombia the harm that the global drug trade causes to both individuals and entire nations, and Colombia has taken an important leadership role in encouraging a new and more progressive global approach.
“This week’s meetings represent an important first step in identifying global solutions and encouraging individual nations to address the challenge in a progressive manner that benefits individual citizens and helps build healthy nations. It is important that Colombia continues its global leadership.
“Within its own borders, Colombia has already recognized the importance of eliminating the black market trade in cannabis and encouraging the development of a medically based cannabis economy that benefits all Colombian citizens. PharmaCielo Ltd. is proud to be among the first applicants for manufacturing and cultivation licences.
“PharmaCielo Ltd. is committed to the development of high-quality, medicinal-grade cannabis oil extracts and we look forward to the continued global leadership of the Government of Colombia.”
About PharmaCielo Ltd.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada. Wholly owned subsidiary PharmaCielo Colombia Holdings S.A.S maintains operations in Rionegro, Colombia and has applied for licences from the Colombian government with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors of standardized medical cannabis products, finished goods producers, research organizations and pharmaceutical companies.
The boards of directors and executive teams of PharmaCielo Ltd. and PharmaCielo Colombia are comprised of a diversely talented group of international business executives and specialists with the relevant expertise to ensure long-term success. The team recognized the significant role Colombia’s ideal location would play in building a sustainable business in the medical cannabis industry and has built a strong business plan focused on supplying the international medical marketplace.
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.